At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 65 enrolled
Drug / intervention
AT-752 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating AT-752 and Placebo for Dengue. Completed, enrolled 65 participants across 1 site.
Detailed Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionNov 2021
TodayJul 2026
First PostedJan 25, 2021
Enrollment StartMar 9, 2021
Primary CompletionNov 14, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.4 years ago
Interventions
AT-752drug
Parallel Assignment
Placebodrug
Parallel Assignment